Aurovela Fe 1/20

Endometriosis, Low Testosterone, Osteoporosis + 16 more

Treatment

20 Active Studies for Aurovela Fe 1/20

What is Aurovela Fe 1/20

Norethisterone

The Generic name of this drug

Treatment Summary

Norethisterone (also known as norethindrone) is a type of synthetic hormone used to treat menstrual irregularities, endometriosis, and as part of contraceptive and hormone replacement therapy. It was first developed in 1951, but wasn't marketed for contraception until 1962. Norethisterone is a second-generation progestin that mimics the actions of natural progesterone, with greater potency.

Necon

is the brand name

image of different drug pills on a surface

Aurovela Fe 1/20 Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Necon

Norethisterone

1967

347

Effectiveness

How Aurovela Fe 1/20 Affects Patients

Norethisterone is a type of pill taken by mouth that contains hormones. It is prescribed to help with contraception, or to treat hormone-related issues such as menopause or endometriosis. This medication works like the body's natural hormone progesterone, but is much more powerful. It helps to regulate the hormones in the body that are related to ovulation and other fertility factors. Taking norethisterone may slightly increase the risk of developing breast cancer. People taking this medication should be aware of this fact and perform regular breast self-exams to check for any lumps or masses.

How Aurovela Fe 1/20 works in the body

Norethisterone works on target cells in the reproductive tract, breast, pituitary, hypothalamus, skeletal tissue and central nervous system. It increases the thickness of cervical mucus to stop sperm from entering the uterus and makes it difficult for a fertilized egg to implant. It also suppresses follicle-stimulating hormone (FSH) and luteinizing hormone (LH), which prevents ovulation and corpus luteum development. When used as part of hormone replacement therapy, it prevents endometrial hyperplasia and lowers the risk of endometrial cancer in postmenopausal women. It also has a

When to interrupt dosage

The dosage of Aurovela Fe 1/20 is contingent upon the diagnosed condition, comprising Atrophic, Fracture and Hormone Replacement Therapy. The measure likewise fluctuates as per the technique of administration (e.g. Oral or Tablet) featured in the table beneath.

Condition

Dosage

Administration

Therapeutic procedure

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Tablet, chewable, Tablet, chewable - Oral, Patch - Transdermal, Patch, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Fracture

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Tablet, chewable, Tablet, chewable - Oral, Patch - Transdermal, Patch, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Osteoporosis

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Tablet, chewable, Tablet, chewable - Oral, Patch - Transdermal, Patch, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Atrophic

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Tablet, chewable, Tablet, chewable - Oral, Patch - Transdermal, Patch, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Hormone Replacement Therapy

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Tablet, chewable, Tablet, chewable - Oral, Patch - Transdermal, Patch, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Endometriosis

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Tablet, chewable, Tablet, chewable - Oral, Patch - Transdermal, Patch, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Hot flashes

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Tablet, chewable, Tablet, chewable - Oral, Patch - Transdermal, Patch, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Low Testosterone

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

hypoestrogenism

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Tablet, chewable, Tablet, chewable - Oral, Patch - Transdermal, Patch, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Vasomotor System

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Tablet, chewable, Tablet, chewable - Oral, Patch - Transdermal, Patch, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Birth Control

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Tablet, chewable, Tablet, chewable - Oral, Patch - Transdermal, Patch, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

female castration

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Tablet, chewable, Tablet, chewable - Oral, Patch - Transdermal, Patch, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Primary Ovarian Insufficiency

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Tablet, chewable, Tablet, chewable - Oral, Patch - Transdermal, Patch, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Osteoporosis, Postmenopausal

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Tablet, chewable, Tablet, chewable - Oral, Patch - Transdermal, Patch, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Oral Contraceptives

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Tablet, chewable, Tablet, chewable - Oral, Patch - Transdermal, Patch, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Hormonal Contraception

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Tablet, chewable, Tablet, chewable - Oral, Patch - Transdermal, Patch, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Estrogen Deprivation Symptoms

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Tablet, chewable, Tablet, chewable - Oral, Patch - Transdermal, Patch, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Menopause

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Tablet, chewable, Tablet, chewable - Oral, Patch - Transdermal, Patch, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Endometriosis

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Warnings

Aurovela Fe 1/20 has eight contraindications, so it should not be taken when enduring any of the conditions outlined in the table below.

Aurovela Fe 1/20 Contraindications

Condition

Risk Level

Notes

Liver Diseases

Do Not Combine

Thrombophilia

Do Not Combine

Vaginal Hemorrhage

Do Not Combine

Malignant Neoplasms

Do Not Combine

Benign hepatic neoplasm

Do Not Combine

Breast Cancer

Do Not Combine

Thromboembolism

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Norethisterone may interact with Pulse Frequency

There are 20 known major drug interactions with Aurovela Fe 1/20.

Common Aurovela Fe 1/20 Drug Interactions

Drug Name

Risk Level

Description

Astemizole

Major

The metabolism of Astemizole can be decreased when combined with Norethisterone.

Axitinib

Major

The metabolism of Axitinib can be decreased when combined with Norethisterone.

Cabazitaxel

Major

The metabolism of Cabazitaxel can be decreased when combined with Norethisterone.

Clomipramine

Major

The metabolism of Clomipramine can be increased when combined with Norethisterone.

Copanlisib

Major

The metabolism of Copanlisib can be decreased when combined with Norethisterone.

Aurovela Fe 1/20 Toxicity & Overdose Risk

The lowest toxic dose of oral contraceptives in mice is 6 g/kg and 42 mg/kg in women. So far, there have been no reports of serious consequences following an overdose of oral contraceptives, even if taken by children. However, symptoms of overdosage may include nausea and/or vomiting.

image of a doctor in a lab doing drug, clinical research

Aurovela Fe 1/20 Novel Uses: Which Conditions Have a Clinical Trial Featuring Aurovela Fe 1/20?

160 active studies are currently examining the efficacy of Aurovela Fe 1/20 for Birth Control, Atrophic Conditions and Low Testosterone Levels.

Condition

Clinical Trials

Trial Phases

Osteoporosis

25 Actively Recruiting

Not Applicable, Phase 4, Phase 1, Phase 2

Birth Control

14 Actively Recruiting

Not Applicable, Phase 3, Phase 4, Phase 2

female castration

0 Actively Recruiting

Hot flashes

30 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Early Phase 1, Phase 3, Phase 1

Low Testosterone

4 Actively Recruiting

Phase 1, Phase 4, Phase 2, Phase 3

Endometriosis

28 Actively Recruiting

Phase 3, Not Applicable, Phase 4, Early Phase 1, Phase 2, Phase 1

Oral Contraceptives

0 Actively Recruiting

Endometriosis

2 Actively Recruiting

Not Applicable, Phase 2

Estrogen Deprivation Symptoms

0 Actively Recruiting

Osteoporosis, Postmenopausal

0 Actively Recruiting

Atrophic

4 Actively Recruiting

Phase 3, Phase 4, Not Applicable

Hormone Replacement Therapy

0 Actively Recruiting

Hormonal Contraception

0 Actively Recruiting

hypoestrogenism

1 Actively Recruiting

Phase 4

Fracture

0 Actively Recruiting

Vasomotor System

0 Actively Recruiting

Primary Ovarian Insufficiency

0 Actively Recruiting

Therapeutic procedure

0 Actively Recruiting

Menopause

0 Actively Recruiting

Aurovela Fe 1/20 Reviews: What are patients saying about Aurovela Fe 1/20?

3.3

Patient Review

2/12/2022

Aurovela Fe 1/20 for Endometriosis

If you're an hour late taking the medication, you will start your period.

2.7

Patient Review

8/6/2021

Aurovela Fe 1/20 for Birth Control

I unfortunately gained a lot of weight while on this pill; however, it did make my periods lighter and shorter.

1.3

Patient Review

5/8/2022

Aurovela Fe 1/20 for Birth Control

I became incredibly anxious and depressed after taking this medication, to the point where I started having suicidal thoughts. It was honestly the worst experience of my life and I would never recommend it to anyone.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about aurovela fe 1/20

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does Aurovela Fe 1/20 prevent pregnancy?

"Aurovela Fe 1/20 is a product that helps to prevent pregnancy in women. It is indicated for use by women who elect to use oral contraceptives as a method of contraception. Oral contraceptives are highly effective."

Answered by AI

What is the generic name for Aurovela Fe 1 20?

"Aurovela Fe 1 / 20 is a combination of ethinyl estradiol and norethindrone. It is used as an contraception to prevent pregnancy."

Answered by AI

What are the side effects of Aurovela Fe 1 20?

"Side effects may include nausea, vomiting, headache, bloating, breast tenderness, fluid retention, or weight change. Spotting or missed/irregular periods may occur, especially during the first few months of use."

Answered by AI

What kind of birth control is Aurovela 1 20?

"This medication contains a combination of two hormones, progestin and estrogen, which are used to prevent pregnancy. In addition to preventing pregnancy, birth control pills can also make your periods more regular, decrease blood loss and pain during periods, and decrease your risk of developing ovarian cysts. This medication can also be used to treat acne."

Answered by AI

Clinical Trials for Aurovela Fe 1/20

Image of Alethios in San Francisco, United States.

Fiber Supplement for Endometriosis

18 - 45
Female
San Francisco, CA

This study is a double-blind, randomized, placebo-controlled study that evaluates the safety and tolerability of a fiber-based dietary supplement and the mechanistic and structure-function effects of that supplement on the gut and vaginal microbiome, gastrointestinal well-being, and quality-of-life parameters in 140 women with endometriosis and co-existing gastrointestinal symptoms over 12 weeks. The primary objective is to evaluate the safety and tolerability of the supplement, measured by the incidence and severity of gastrointestinal adverse events (AEs) and discontinuations. Secondary objectives include assessing the fibers impact on gastrointestinal symptoms and quality of life through the use of custom questionnaires built for the study population and evaluation of other endometriosis related parameters such as pelvic discomfort. Exploratory objectives focus on the exploration of the gut and vaginal microbiomes, their connection to endometriosis, and how they are impacted by the study product.

Recruiting
Paid Trial

Alethios

Bryce Jarman, PhD

Alethios, Inc.

Image of St. Joseph's Healthcare Hamilton in Hamilton, Canada.

Internet-Delivered Cognitive Behavioural Therapy for Hot Flashes

40 - 60
Female
Hamilton, Canada

Given the impact that hot flashes and night sweats can have on daily life during the menopausal transition, our team has developed a therapist-guided online cognitive behavioural therapy (CBT)- based program to help individuals manage these symptoms. An online program may help address systemic barriers to in-person care, such as cost, time, travel, and caregiving needs. The broad aim of this pilot clinical trial is to examine the experience of a four-week therapist-guided online CBT-based program for menopause-related hot flashes and night sweats. The primary objective of this study is to evaluate the acceptability and feasibility of the four-week online program, including how participants experience the program and how well they are able to complete it at home. The secondary objective is to explore whether the program may help with hot flashes and night sweats, and related concerns such as sleep, mood, anxiety, and quality of life. Exploratory analyses will examine whether changes in these outcomes are maintained three months after completing the program. Researchers will compare participants who receive the program immediately with participants who wait four weeks before receiving it. Participants will: * Complete online questionnaires about their symptoms and well-being. * Complete four weekly online lessons and activities. * Meet briefly with a guide each week for guidance and support. * Complete follow-up questionnaires after the program and three months later.

Waitlist Available
Has No Placebo

St. Joseph's Healthcare Hamilton

Sheryl M Green, PhD, CPsych

Image of MusB Research LLC in New Port Richey, United States.

Ashoka Bark and Shatavari for Menopause

40 - 65
Female
New Port Richey, FL

This 12-week randomized, placebo-controlled clinical trial will evaluate the efficacy and safety of a daily oral supplement containing Ashoka Bark and Shatavari in women experiencing menopausal symptoms. Up to 50 participants will be randomized to receive either the active supplement or placebo, with 40 participants expected to complete the study. Participants will attend visits at Weeks 0, 6, and 12, where hormone levels (FSH and estradiol), menopausal symptoms, quality of life, anxiety, cognitive function, and sleep will be assessed using validated measures. The study will also explore changes in the vaginal microbiome and monitor safety and adherence throughout the trial. The study will be conducted at MusB Research in New Port Richey, Florida.

Recruiting
New This Month

MusB Research LLC

Vidya USA Corporation

Image of Alberta Diabetes Institute in Edmonton, Canada.

Resistance Exercise for Type 1 Diabetes

18+
Female
Edmonton, Canada

Improvements in diabetes care and technology have led to people with type 1 diabetes living longer. There are now more seniors than ever living with this complex health condition. With aging, type 1 diabetes affects both bone (more brittle), and muscle (loss of size and strength). This loss happens faster and to a greater extent in females than in males, and greatly increases the risk of frailty and falls. It may also occur more quickly in individuals who have higher blood glucose (sugar) levels. Frailty is an important factor to address. In older females, even mild frailty decreases the ability to perform day-to-day tasks, and increases the risk of fractures, falls, hospitalization, and even death. Performing regular exercise helps to maintain the strength and quality of both muscles and bones with aging. The best type of exercise to help maintain the ability to perform activities of daily living (known as functional mobility) for this population is currently unknown. Resistance exercise (weightlifting) helps to prevent decreases in mobility in seniors without diabetes. However, in the context of type 1 diabetes, high blood sugar levels could negatively impact these potential strength benefits and low blood glucose could lead to falls. As such, any exercise program that causes swings in glucose levels may hinder rather than help. The goal of this study is to evaluate the effect of weightlifting over a 6-month timeframe on functional mobility in postmenopausal females with type 1 diabetes, compared to a group that does not train. the investigators will also assess its effects on blood sugar variability and the risk of hypoglycemia. Like different medications, not all exercise is equal. Creating more knowledge about the benefits of specific types of exercise in this population will allow us to be more precise in our exercise recommendations for living longer and more independently with type 1 diabetes.

Waitlist Available
Has No Placebo

Alberta Diabetes Institute (+2 Sites)

Jane E Yardley, PhD

Have you considered Aurovela Fe 1/20 clinical trials?

We made a collection of clinical trials featuring Aurovela Fe 1/20, we think they might fit your search criteria.
Go to Trials
Image of University of Alberta in Edmonton, Canada.

Pelvic Floor Physical Therapy for Endometriosis

18 - 50
Female
Edmonton, Canada

Endometriosis is a chronic inflammatory condition where there is abnormal tissue growing in the pelvis or other places in the body that resembles the lining of the uterus (endometrium), and is a common cause of long lasting pelvic pain. Surgery is sometimes done for endometriosis to help people with pain, however it is common for people to have some pain after surgery that doesn't go away. This may be related to other painful things like muscle pain in the pelvis, bowel or bladder issues, or mental health conditions. Researchers would like to know if doing pelvic floor physiotherapy before surgery for endometriosis will help people with long lasting pain after surgery. Participants in the study will be randomly put into one of two groups: the intervention group, who will receive two to three structured in-person pelvic floor physiotherapy sessions prior to surgery ("prehabilitation"), in addition to usual surgical care, or the control group, who will receive usual surgical care, and may still access physiotherapy outside of the study if they want to. All participants will complete questionnaires before surgery, after completing prehabilitation or immediately before surgery if they are part of the control group, approximately 6 weeks after surgery, 6 months after surgery, and 12 months after surgery. The questionnaires ask about endometriosis-related pain, quality of life, bladder and bowel symptoms, and mental well-being.

Waitlist Available
Has No Placebo

University of Alberta

Alicia Long, MD, MSc, FRCSC

Image of Icahn School of Medicine at Mount Sinai in New York, United States.

Personalized Exercise for Chronic Pelvic Pain

18 - 55
Female
New York, NY

WorkoutCPP is a pilot study evaluating the feasibility of a personalized exercise recommendation system for individuals with chronic pelvic pain disorders (CPPDs). The study uses reinforcement learning (RL), a type of artificial intelligence that adapts recommendations over time based on each participant's reported pain levels, symptom burden, and exercise compliance. Participants receive daily exercise recommendations that alternate between standard, non-personalized guidance and personalized, RL-generated recommendations across four 2-week phases, allowing within-person comparison of outcomes under each condition. The primary hypothesis is that an RL-based adaptive recommendation system is feasible to deliver in a CPPD population.

Recruiting
Has No Placebo

Icahn School of Medicine at Mount Sinai

Ipek Ensari, PhD

Have you considered Aurovela Fe 1/20 clinical trials?

We made a collection of clinical trials featuring Aurovela Fe 1/20, we think they might fit your search criteria.
Go to Trials
Image of Novum Pharmaceutical Research Services in Las Vegas, United States.

Estradiol/Levonorgestrel Patch for Menopause

40 - 75
Female
Las Vegas, NV

The two products used in this study are transdermal patches that contain selegiline. The test drug is the Estradiol/Levonorgestrel Transdermal Delivery System (TDS). The comparator drug is the Climara Pro® TDS. The purpose of this research study is to compare how the skin tolerates the test TDS and the comparator TDS. The study will evaluate and compare skin irritation and possible allergic-type skin reactions (sensitization) caused by the two products. The comparison will be based on how the skin responds to repeated applications of each TDS. This includes the assessment of skin irritation during the Induction Period and the evaluation of possible allergic or sensitization reactions after the Challenge Period. In addition, the adhesion of each patch (how well the patch sticks to the skin over time) will be regularly checked, as this is important for both product performance and skin safety.

Phase 1
Recruiting

Novum Pharmaceutical Research Services

Corium Innovations, Inc.

Image of Clinical and Translational Science Center, Weill Cornell Medical College in New York, United States.

Treatment for Menopause

40 - 90
Female
New York, NY

This study will compare adherence, tolerability, safety, and treatment satisfaction between a calcium-rich food and a traditional calcium carbonate supplement in women ages 40 to 90 who are at increased risk for osteoporosis. Participants will be randomly assigned to receive either a calcium-rich food providing 500 mg of calcium from milk-derived minerals or a 500 mg calcium carbonate supplement once daily for four weeks. Participants will complete brief weekly questionnaires assessing supplement use, gastrointestinal symptoms, and treatment satisfaction. The goal of the study is to determine whether the form in which calcium is consumed influences adherence and participant experience. No blood draws, imaging studies, or other invasive procedures are involved

Waitlist Available
Has No Placebo

Clinical and Translational Science Center, Weill Cornell Medical College

Jeff Zhu

Image of Rocky Mountain Regional VA Medical Center, Aurora, CO in Aurora, United States.

Testosterone Therapy for Spinal Cord Injury

18+
Male
Aurora, CO

Spinal cord injury (SCI) results in lower limb muscle loss, bone loss, and high fat mass that impede the recovery of physical function, increase bone fracture risk, and worsen health and quality of life. These deficits result from reduced activity after SCI and may be worsened by low testosterone, which is present in many men with SCI. In older men with low testosterone who do not have SCI, testosterone therapy (TRT) is known to increase muscle mass, muscle strength, and bone mineral density, and to reduce body fat. However, it is not known if TRT is effective in men with SCI. The purposes of this study are to determine the effectiveness of TRT in men who have low testosterone and difficulty walking after chronic motor incomplete SCI and to assess whether a process in the body that changes testosterone to dihydrotestosterone (DHT; another hormone that is stronger than testosterone) impacts the effectiveness of TRT in the impaired lower limbs and in other tissues after SCI. The researchers hypothesize that TRT will improve muscle and bone in the impaired limbs of men with chronic incomplete SCI and reduce fat mass, and that finasteride (a drug that blocks that blocks a process that changes testosterone to DHT) will influence prostate symptoms but not the musculoskeletal or body composition benefits produced by TRT.

Phase 2 & 3
Waitlist Available

Rocky Mountain Regional VA Medical Center, Aurora, CO (+3 Sites)

Joshua F Yarrow, PhD MS BS

Image of UConn Health in Farmington, United States.

Educational Videos for Pre-operative Anxiety

18+
Female
Farmington, CT

The goal of this clinical trial is to learn if educational videos can reduce pre-operative anxiety in patients undergoing minimally invasive gynecologic surgery. The main question it aims to answer are: do patient education videos decrease preoperative anxiety? do patient education videos increase patient preparedness for surgery? Researchers will compare the group who watched the videos preoperatively to the group who only underwent the usual counseling at the preoperative visit to see if the results of a survey that measures anxiety and preparedness differ. Participants will be randomly assigned to one of two groups: one group that will be asked to watch the educational videos and one group that will not. All participants will attend their pre-operative appointment as usual and complete a survey afterwards.

Waitlist Available
Has No Placebo

UConn Health

Have you considered Aurovela Fe 1/20 clinical trials?

We made a collection of clinical trials featuring Aurovela Fe 1/20, we think they might fit your search criteria.
Go to Trials